Every Form 4 that Harrow Health Inc (HROW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HROW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HROW filings page.
HARROW, INC. executive Amir Shojaei, Chief Scientific Officer, exercised 11,250 stock options for common stock at an exercise price of $35.96 per share on August 14, 2026. The resulting 11,250 common shares were then sold at $40.00 per share in a broker-assisted same-day sale to fund the aggregate exercise price and related transaction costs, and Shojaei did not retain any of the shares acquired upon exercise. After the transaction, 18,750 stock options under this award remain outstanding, with the option originally granted on January 6, 2025 and vesting through January 6, 2029.
Sternberg Perry J. reported acquisition or exercise transactions in this Form 4 filing.
Harrow, Inc. director Perry J. Sternberg reported receiving a grant of 5,248 restricted stock units as compensation for services. These RSUs vest in equal quarterly installments over one year from the grant date, with the underlying common shares delivered only after his service with the company ends.
SILVERNAIL LAUREN P reported acquisition or exercise transactions in this Form 4 filing.
Harrow, Inc. director Lauren P. Silvernail received a grant of 5,248 restricted stock units as equity compensation for services. These RSUs vest in equal quarterly installments over one year from the grant date, and the underlying shares will not be delivered, transferred, or sold until service terminates.
Graves Adrienne L reported acquisition or exercise transactions in this Form 4 filing.
Harrow, Inc. director Adrienne L. Graves received a grant of 5,248 Restricted Stock Units as compensation for services. These RSUs vest in equal quarterly installments over one year from the grant date, and the underlying shares will be delivered only upon termination of service and cannot be transferred or sold before then.
Harrow, Inc. director Adrienne L. Graves bought 1,000 shares of common stock in an open-market transaction at $31.07 per share. This purchase on May 18, 2026 brings her directly held stake to 1,000 shares, indicating a new personal equity position in the company.
Harrow, Inc. director Lauren P. Silvernail purchased 1,000 shares of Harrow common stock in an open-market transaction at $31.00 per share. Following this transaction, Silvernail directly owns 1,000 common shares, indicating this filing reflects an initial reported stake rather than a large position change.
Shojaei Amir reported acquisition or exercise transactions in this Form 4 filing.
Harrow, Inc. reported that Chief Scientific Officer Amir Shojaei received a grant of 10,000 restricted stock units, each representing a right to one share of common stock. These RSUs vest in full on May 15, 2029, contingent on his continued service, and reflect compensation rather than open-market trading.
Harrow, Inc.'s Chief Executive Officer Mark L. Baum reported an open-market purchase of 10,000 shares of common stock at a weighted average price of $30.20 per share. After this transaction, he directly owns 2,996,130 shares. The filing notes the shares were bought in multiple trades between $30.18 and $30.34 per share.
Harrow, Inc.’s president and CFO, Andrew R. Boll, bought additional company stock. On May 14, 2026, he made open-market purchases totaling 3,500 shares of Harrow common stock at a price of $29.90 per share. After these transactions, he directly owns 814,679 Harrow common shares.
The filing notes the 3,500 shares reflect two separate open-market trades on that date, each executed at $29.90 per share, and indicates that detailed trade information is available upon request.
Opaleye Management Inc., a 10% owner of HARROW, INC., reported open-market sales of Harrow common stock through affiliated entities on March 3 and 4, 2026.
Opaleye, L.P. sold 59,000 and 134,000 shares at weighted average prices of $39.1524 and $39.6721, while a separately managed account sold 1,309 and 4,263 shares at the same respective weighted average prices. In total, 198,572 shares were sold in multiple transactions within disclosed price ranges.
HARROW, INC. insider Opaleye Management Inc., as portfolio manager of a separately managed account, reported an open-market sale of 5,000 shares of common stock on February 27, 2026 at a price of $54.18 per share.
After this sale, the managed account held 65,000 shares indirectly attributed to Opaleye. A separate holding of 3,815,000 shares is owned directly by Opaleye, L.P., for which Opaleye Management Inc. is the investment manager. Opaleye Management Inc. disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest.
Harrow, Inc.’s chief commercial officer, Patrick William Sullivan, received two new restricted stock unit awards. On 01/30/2026 he was granted 25,000 RSUs and 15,000 RSUs under the company’s 2025 Incentive and Awards Plan, each RSU representing one share of Harrow common stock upon vesting.
The 25,000 RSUs have a five-year term and vest only if Harrow’s revenue reaches $230,000,000 in a single calendar quarterly period, tying this award directly to a significant revenue milestone. The 15,000 RSUs will vest in full three years after the grant date, on 01/30/2029, providing longer-term equity-based compensation. Both awards are held directly by Sullivan.
Harrow, Inc. insider Opaleye Management Inc., a 10% owner, reported an indirect sale of Harrow common stock. On January 6, 2026, a separately managed account for which Opaleye acts as portfolio manager sold 20,000 shares of common stock at a weighted average price of $53.3457 per share. After this transaction, the managed account held 70,000 shares indirectly attributed to Opaleye. Separately, 3,815,000 shares were reported as owned by Opaleye, L.P., for which Opaleye Management Inc. is the investment manager. Opaleye Management Inc. states it may be deemed a beneficial owner through these roles but disclaims beneficial ownership beyond its pecuniary interest.
Harrow, Inc. reported that its president and CFO, Andrew R. Boll, exercised 60,000 stock options on 12/12/2025 at an exercise price of $3.95 per share, receiving the same number of common shares.
The options were originally granted on April 1, 2016 under the company’s 2007 Stock Incentive and Awards Plan and vested quarterly over three years. In connection with the exercise, 26,665 shares were withheld to cover the exercise price and tax liability, and the filing states this withholding did not involve any market sales or other market transactions. After these transactions, Boll beneficially owns 811,179 shares of Harrow common stock directly.
Harrow, Inc.'s chief executive officer and director Mark L. Baum reported exercising stock options for 180,000 shares of common stock at $3.95 per share.
After this option exercise and the withholding of 79,994 shares to satisfy the exercise price and tax obligations, he directly owns 2,986,130 shares of Harrow common stock. The company notes that the share withholding did not involve any market sales or other market transactions.